MDMA (Ecstasy) tablets collected in the UK between 2001 and 2018 show increasing MDMA content over time, with median free-base content exceeding 100 mg for the first time in 2018. Analysis of 412 tablets revealed dramatic within-batch content variability, with differences up to 136 mg. Dissolution testing on 247 tablets showed that tablets can be categorized as fast-, intermediate-, or slow-releasing, but no tablet characteristics predicted dissolution classification, meaning users cannot know a tablet's release profile beforehand. Within-batch variation in dissolution rate was also observed. Rapid assessment of MDMA content alone does not account for variability in remaining tablets in a batch or dissolution profiles. High-content, slow-releasing tablets may cause delayed or prolonged toxicity, increasing risk of re-dosing if absorption is delayed.
A method for measuring MDMA content in ecstasy tablets using a compact 60 MHz benchtop NMR spectrometer was validated against UNODC guidelines. The method showed good specificity, selectivity, linearity, precision, and accuracy. Among seized tablets, the lowest MDMA free base detected was 9.35 mg in a piperazine mix, and the highest was 237.55 mg. The median MDMA amount in 2022 was 9.1% lower than pre-pandemic 2019 data but still higher than the 105 mg median reported in 2018. Within-batch variation was insignificant for one seizure but greater for another, indicating a single tablet's content may not represent the whole batch. The upward dosage trend underscores the need for ongoing monitoring and prevention interventions.